210 related articles for article (PubMed ID: 21443478)
1. Possibilities of poly(D,L-lactide-co-glycolide) in the formulation of nanomedicines against cancer.
Holgado MA; Alvarez-Fuentes J; Fernández-Arévalo M; Arias JL
Curr Drug Targets; 2011 Jul; 12(8):1096-111. PubMed ID: 21443478
[TBL] [Abstract][Full Text] [Related]
2. Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems.
Patel RB; Carlson AN; Solorio L; Exner AA
J Biomed Mater Res A; 2010 Aug; 94(2):476-84. PubMed ID: 20186771
[TBL] [Abstract][Full Text] [Related]
3. PLGA-based nanoparticles as cancer drug delivery systems.
Sadat Tabatabaei Mirakabad F; Nejati-Koshki K; Akbarzadeh A; Yamchi MR; Milani M; Zarghami N; Zeighamian V; Rahimzadeh A; Alimohammadi S; Hanifehpour Y; Joo SW
Asian Pac J Cancer Prev; 2014; 15(2):517-35. PubMed ID: 24568455
[TBL] [Abstract][Full Text] [Related]
4. Poly(D,L-lactide-co-glycolide) nanoparticles encapsulated fluorescent isothiocyanate and paclitaxol: preparation, release kinetics and anticancer effect.
Yang H; Li K; Liu Y; Liu Z; Miyoshi H
J Nanosci Nanotechnol; 2009 Jan; 9(1):282-7. PubMed ID: 19441308
[TBL] [Abstract][Full Text] [Related]
5. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
6. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.
Jain RA
Biomaterials; 2000 Dec; 21(23):2475-90. PubMed ID: 11055295
[TBL] [Abstract][Full Text] [Related]
7. CD44 targeted PLGA nanomedicines for cancer chemotherapy.
Saneja A; Arora D; Kumar R; Dubey RD; Panda AK; Gupta PN
Eur J Pharm Sci; 2018 Aug; 121():47-58. PubMed ID: 29777858
[TBL] [Abstract][Full Text] [Related]
8. PLGA Nanoparticles and Their Versatile Role in Anticancer Drug Delivery.
Khan I; Gothwal A; Sharma AK; Kesharwani P; Gupta L; Iyer AK; Gupta U
Crit Rev Ther Drug Carrier Syst; 2016; 33(2):159-93. PubMed ID: 27651101
[TBL] [Abstract][Full Text] [Related]
9. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
10. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents.
Dinarvand R; Sepehri N; Manoochehri S; Rouhani H; Atyabi F
Int J Nanomedicine; 2011; 6():877-95. PubMed ID: 21720501
[TBL] [Abstract][Full Text] [Related]
11. Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide.
Graves RA; Ledet GA; Glotser EY; Mitchner DM; Bostanian LA; Mandal TK
Eur J Pharm Sci; 2015 Aug; 76():1-9. PubMed ID: 25933716
[TBL] [Abstract][Full Text] [Related]
12. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions.
Liu SQ; Tong YW; Yang YY
Biomaterials; 2005 Aug; 26(24):5064-74. PubMed ID: 15769542
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
14. Stabilisation and determination of the biological activity of L-asparaginase in poly(D,L-lactide-co-glycolide) nanospheres.
Wolf M; Wirth M; Pittner F; Gabor F
Int J Pharm; 2003 Apr; 256(1-2):141-52. PubMed ID: 12695020
[TBL] [Abstract][Full Text] [Related]
15. Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis.
Duvvuri S; Janoria KG; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2007 Jun; 23(3):264-74. PubMed ID: 17593010
[TBL] [Abstract][Full Text] [Related]
16. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.
Acharya S; Sahoo SK
Adv Drug Deliv Rev; 2011 Mar; 63(3):170-83. PubMed ID: 20965219
[TBL] [Abstract][Full Text] [Related]
17. Microencapsulation of chemotherapeutics into monodisperse and tunable biodegradable polymers via electrified liquid jets: control of size, shape, and drug release.
Fattahi P; Borhan A; Abidian MR
Adv Mater; 2013 Sep; 25(33):4555-60. PubMed ID: 23824544
[TBL] [Abstract][Full Text] [Related]
18. Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres.
Sánchez A; Villamayor B; Guo Y; McIver J; Alonso MJ
Int J Pharm; 1999 Aug; 185(2):255-66. PubMed ID: 10460920
[TBL] [Abstract][Full Text] [Related]
19. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
Desai KG; Mallery SR; Schwendeman SP
Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles made of fluorescence-labelled Poly(L-lactide-co-glycolide): preparation, stability, and biocompatibility.
Weiss B; Schaefer UF; Zapp J; Lamprecht A; Stallmach A; Lehr CM
J Nanosci Nanotechnol; 2006; 6(9-10):3048-56. PubMed ID: 17048517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
